Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + Fruquintinib in Advanced Solid Tumors
NCT04716634Phase 2Completed
- Sponsor
- BeiGene
- Start
- Apr 2021
- Primary completion
- Feb 2024
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of tislelizumab, fruquintinib in gastric cancer (GC), colorectal cancer (CRC), non-small cell lung cancer (NSCLC), sponsored by BeiGene. Started Apr 2021; status: completed.
02
Drugs
tislelizumabfruquintinib
03
Conditions
gastric cancer (GC)colorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04716634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04716634.